ASCO said it will not recommend Grail’s Galleri test for population screening after the NHS-Galleri trial failed to meet its primary endpoint. The decision comes as the controversy continues over how to interpret the trial’s secondary patterns, including shifts in stage distribution after three years of screening. ASCO leadership said the assay should not be included in screening guidelines “at this time,” even while acknowledging the data are “encouraging” regarding reductions in stage IV cancers and potential detection of earlier-stage disease.